Treace Announces Participation in the Morgan Stanley 20th Annual Global Healthcare Conference

Rhea-AI Summary

Treace Medical Concepts (TMCI) announced that CEO John T. Treace and CFO Mark L. Hair will participate in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on September 13, 2022, at 8:35 am ET. This event will highlight the company’s advancements in the surgical treatment of hallux valgus (bunions) through its patented Lapiplasty® 3D Bunion Correction™ procedure. A live webcast will be available on the company’s investor relations website.

Positive

• Participation in a significant healthcare conference may enhance visibility and investor interest.
• Treace's innovative Lapiplasty® 3D Bunion Correction™ system addresses a widespread medical issue affecting millions.

Negative

• None.

PONTE VEDRA, Fla., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Treace Medical Concepts, Inc. (“Treace”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of hallux valgus (commonly known as bunions) through its Lapiplasty® 3D Bunion Correction™ procedure, today announced that John T. Treace, Chief Executive Officer, and Mark L. Hair, Chief Financial Officer, will participate in a fireside chat at the Morgan Stanley 20^th Annual Global Healthcare Conference on Tuesday, September 13, 2022, beginning at approximately 8:35 am ET.

A live webcast and replay of the fireside chat will be available on the Company’s investors relations website at https://investors.treace.com/.

About Treace Medical Concepts
Treace Medical Concepts, Inc. is a medical technology company with the goal of advancing the standard of care for the surgical management of bunion deformities and related midfoot correction. Bunions are complex 3-dimensional deformities that originate from an unstable joint in the middle of the foot and affect approximately 65 million Americans, of which Treace estimates 1.1 million are annual surgical candidates. Treace has pioneered and patented the Lapiplasty® 3D Bunion Correction™ system – a combination of instruments, implants, and surgical methods designed to surgically correct all 3 planes of the bunion deformity and secure the unstable joint, addressing the root cause of the bunion and helping patients get back to their active lifestyles. Treace recently expanded its offering with the Adductoplasty™ Midfoot Correction System, designed for reproducible surgical correction of the midfoot to provide further support to hallux valgus patients. For more information, please visit www.treace.com.

Contacts:
Treace Medical Concepts
Mark L. Hair
Chief Financial Officer
mhair@treace.net
(904) 373-5940

Investors:
Gilmartin Group
Lynn Lewis or Vivian Cervantes
IR@treace.net

FAQ

What event will Treace Medical Concepts participate in on September 13, 2022?

Treace Medical Concepts will participate in the Morgan Stanley 20th Annual Global Healthcare Conference.

Who will represent Treace Medical Concepts at the Morgan Stanley conference?

CEO John T. Treace and CFO Mark L. Hair will represent the company.

What is the focus of Treace Medical Concepts' presentation at the conference?

The focus will be on Treace's advancements in the surgical treatment of hallux valgus through the Lapiplasty® procedure.

Where can I watch the Treace Medical Concepts fireside chat?

The fireside chat will be broadcast live on Treace's investor relations website.

What is hallux valgus?

Hallux valgus, commonly known as bunions, is a common foot deformity affecting millions of people.